Nuevocor, a Singapore-based biotech company specializing in developing therapies for patients with heart diseases, announced its appointment of Al Gianchetti to the role of chief executive officer. Alongside taking the helm as CEO, Gianchetti will also retain a seat on the company’s board.
Nuevocor focuses on developing novel treatments for conditions that do not already have effective treatments on the market. Its work hinges on the aberrant mechanobiology that drives disease progression. The company is currently initiating its first clinical trial with NVC-001, a gene therapy for dilated cardiomyopathy.
Gianchetti joins the company from his previous role as president and CEO of XyloCor Therapeutics. With a total of over three decades of experience in drug development and commercialization, Gianchetti is expected to leverage his expertise to help Nuevocor improve care for patients with rare cardiomyopathies.
